156 related articles for article (PubMed ID: 38608143)
21. Oncogenic-Directed Therapy for Advanced Non-Small Cell Lung Cancer: Implications for the Advanced Practice Nurse.
Davies M
Clin J Oncol Nurs; 2022 Jun; 26(3):245-251. PubMed ID: 35604726
[TBL] [Abstract][Full Text] [Related]
22. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
23. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.
Lim C; Tsao MS; Le LW; Shepherd FA; Feld R; Burkes RL; Liu G; Kamel-Reid S; Hwang D; Tanguay J; da Cunha Santos G; Leighl NB
Ann Oncol; 2015 Jul; 26(7):1415-21. PubMed ID: 25922063
[TBL] [Abstract][Full Text] [Related]
24. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
25. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
Singhi EK; Horn L; Sequist LV; Heymach J; Langer CJ
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e187-e197. PubMed ID: 31099642
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapies for non-small cell lung cancer.
Dempke WC; Suto T; Reck M
Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
[TBL] [Abstract][Full Text] [Related]
27. Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.
Shalata W; Yakobson A; Weissmann S; Oscar E; Iraqi M; Kian W; Peled N; Agbarya A
Oncology; 2022; 100(9):467-474. PubMed ID: 35679833
[No Abstract] [Full Text] [Related]
28. Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.
Adamson RT
Am J Manag Care; 2013 Dec; 19(19 Suppl):s398-404. PubMed ID: 24494721
[TBL] [Abstract][Full Text] [Related]
29. The role of molecular analyses in the era of personalized therapy for advanced NSCLC.
Tanner NT; Pastis NJ; Sherman C; Simon GR; Lewin D; Silvestri GA
Lung Cancer; 2012 May; 76(2):131-7. PubMed ID: 22176813
[TBL] [Abstract][Full Text] [Related]
30. Personalized targeted therapy in advanced non-small cell lung cancer.
Ma PC
Cleve Clin J Med; 2012 May; 79 Electronic Suppl 1():eS56-60. PubMed ID: 22614968
[TBL] [Abstract][Full Text] [Related]
31. NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?
Falk AT; Heeke S; Hofman V; Lespinet V; Ribeyre C; Bordone O; Poudenx M; Otto J; Garnier G; Castelnau O; Guigay J; Leroy S; Marquette CH; Hofman P; Ilié M
Expert Rev Anticancer Ther; 2017 Aug; 17(8):681-685. PubMed ID: 28511612
[TBL] [Abstract][Full Text] [Related]
32. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
33. CURRENT THERAPEUTIC STRATEGIES AND CHALLENGES IN NSCLC TREATMENT: A COMPREHENSIVE REVIEW.
Kumar M; Sarkar A
Exp Oncol; 2022 May; 44(1):7-16. PubMed ID: 35548961
[TBL] [Abstract][Full Text] [Related]
34. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
35. Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC.
Cronemberger E; Baldotto C; Marinho F; De Marchi P; Araújo LH; Franke F; Salles P; Calabrich A; Almeida T; Custodio MG; Maria AS; Pereira MH; Castro G
Clinics (Sao Paulo); 2020; 75():e1777. PubMed ID: 33084767
[TBL] [Abstract][Full Text] [Related]
36. First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Non-Small-cell Lung Cancer With Different Prognostic Significance.
Iams WT; Yu H; Shyr Y; Patil T; Horn L; McCoach C; Kelly K; Doebele RC; Camidge DR
Clin Lung Cancer; 2018 Nov; 19(6):531-543. PubMed ID: 30197261
[TBL] [Abstract][Full Text] [Related]
37. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting.
Presley CJ; Tang D; Soulos PR; Chiang AC; Longtine JA; Adelson KB; Herbst RS; Zhu W; Nussbaum NC; Sorg RA; Agarwala V; Abernethy AP; Gross CP
JAMA; 2018 Aug; 320(5):469-477. PubMed ID: 30088010
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of Atezolizumab for Advanced Non-Small Cell Lung Cancer Based on Clinical and Molecular Features: A Meta-Analysis.
Liu W; Huo G; Chen P
Front Immunol; 2022; 13():909027. PubMed ID: 35799785
[TBL] [Abstract][Full Text] [Related]
39. ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.
Guérin A; Sasane M; Zhang J; Macalalad AR; Galebach P; Jarvis J; Kageleiry A; Culver K; Wu EQ; Wakelee H
Cancer Epidemiol; 2015 Jun; 39(3):307-12. PubMed ID: 25914136
[TBL] [Abstract][Full Text] [Related]
40. A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies.
Chen L; Smith DA; Somarouthu B; Gupta A; Gilani KA; Ramaiya NH
AJR Am J Roentgenol; 2019 Nov; 213(5):1047-1058. PubMed ID: 31361530
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
